Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
Eli Lilly licenses ALS drug program from Alchemab in $415M pact
Four months after Eli Lilly and British biotech Alchemab penned a discovery collab, the Big Pharma is licensing its first drug asset from the deal.
Ben Adams
May 6, 2025 8:54am
Lilly pens $13M upfront oligonucleotide AI pact with Creyon Bio
Apr 29, 2025 10:07am
AstraZeneca culls neuroscience meds in Q1 clear-out
Apr 29, 2025 7:08am
Galapagos CEO eyes exit as spinout names leader—Chutes & Ladders
Apr 25, 2025 8:30am
Lilly's oral GLP-1 delivers Ozempic-like efficacy in phase 3
Apr 17, 2025 6:45am
Verve posts clean PCSK9 editor profile, teeing up Lilly decision
Apr 14, 2025 7:00am
